Advances in the management of higher-risk myelodysplastic syndromes: future prospects

Georgina Gener-Ricos, Juan Jose Rodriguez-Sevilla, Samuel Urrutia, Alex Bataller, Alexandre Bazinet, Guillermo Garcia-Manero

Research output: Contribution to journalReview articlepeer-review

Abstract

Higher-risk myelodysplastic syndromes (HR-MDS) are defined using a number of prognostic scoring systems that include the degree of cytopenias, percentage of blasts, cytogenetic alterations, and more recently genomic data. HR-MDS encompasses characteristics such as progressive cytopenias, increased bone marrow blasts, unfavorable cytogenetics, and an adverse mutational profile. Survival is generally poor, and patients require therapy to improve outcomes. Hypomethylating agents (HMAs), such as azacitidine, decitabine, and more recently, oral decitabine/cedazuridine, are the only approved therapies for HR-MDS. These are often continued until loss of response, progression, or unacceptable toxicity. Combinations including an HMA plus other drugs have been investigated but have not demonstrated better outcomes compared to single-agent HMA. Moreover, in a disease of high genomic complexity such as HR-MDS, therapy targeting specific genomic abnormalities is of interest. This review will examine the biological underpinnings of HR-MDS, its therapeutic landscape in the frontline and relapsed settings, as well as the impact of hematopoietic stem cell transplantation, the only known curative intervention for this disease.

Original languageEnglish
Pages (from-to)1233-1244
Number of pages12
JournalLeukemia and Lymphoma
Volume65
Issue number9
DOIs
StatePublished - 2024

Keywords

  • Higher-risk myelodysplastic syndromes
  • allogeneic stem cell transplant
  • hypomethylating agents
  • targeted therapies

Fingerprint

Dive into the research topics of 'Advances in the management of higher-risk myelodysplastic syndromes: future prospects'. Together they form a unique fingerprint.

Cite this